Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity
Hongxin Huang(Southern Medical University), Zhili Rong(Southern Medical University)
Cited by 52
Related Papers
An Updated Meta-Analysis of Fatal Adverse Events Caused by Bevacizumab Therapy in Cancer Patients
|PLoS ONE|2014|33
Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma
|Frontiers in Oncology|2024|14
Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysis
|Frontiers in Pharmacology|2023|10
hpCasMINI: An engineered hypercompact CRISPR-Cas12f system with boosted gene editing activity
|Nature Communications|2025|5